Multiomic Approaches for Cancer Biomarker Discovery in Liquid Biopsies: Advances and Challenges.
Paola Monterroso DiazAshton LeehansPrashanth RavishankarAnna DailyPublished in: Biomarker insights (2023)
Cancer is a complex and heterogeneous disease that poses a significant threat to global health. Early diagnosis and treatment are critical for improving patient outcomes, and the use of liquid biopsies has emerged as a promising approach for cancer detection and monitoring. Traditionally, cancer diagnosis has relied on invasive tissue biopsies, the collection of which can prove challenging for patients and the results of which may not always provide accurate results due to tumor heterogeneity. Liquid biopsies have gained increasing attention as they provide a non-invasive and accessible source of cancer biomarkers, which can be used to diagnose cancer, monitor treatment response, and detect relapse. The integration of -omics technologies, such as proteomics, genomics, and metabolomics, has further enhanced the capabilities of liquid biopsies by introducing precision oncology and enabling the tailoring of treatment for individual patients based on their unique tumor biology. In this review, we will discuss the challenges and advances in the field of cancer liquid biopsies and the integration of -omics technologies for different types of liquid biopsies, including blood, tear, urine, sweat, saliva, and cerebrospinal fluid.
Keyphrases
- papillary thyroid
- squamous cell
- end stage renal disease
- public health
- single cell
- global health
- chronic kidney disease
- ionic liquid
- small molecule
- ejection fraction
- palliative care
- newly diagnosed
- ultrasound guided
- prognostic factors
- working memory
- patient reported outcomes
- young adults
- smoking cessation
- combination therapy
- sensitive detection